Early prediction of blonanserin response in Japanese patients with schizophrenia

Taro Kishi,1 Yuki Matsuda,1 Kiyoshi Fujita,2,3 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan; 3The Neuroscience Research Center, Toyoake, Aichi, Japan Background: Blo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kishi T, Matsuda Y, Fujita K, Iwata N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/58f3f0ce357944898f5ac8cb40e305f7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:58f3f0ce357944898f5ac8cb40e305f7
record_format	dspace
spelling	oai:doaj.org-article:58f3f0ce357944898f5ac8cb40e305f72021-12-02T11:46:04ZEarly prediction of blonanserin response in Japanese patients with schizophrenia1178-2021https://doaj.org/article/58f3f0ce357944898f5ac8cb40e305f72014-09-01T00:00:00Zhttp://www.dovepress.com/early-prediction-of-blonanserin-response-in-japanese-patients-with-sch-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 Taro Kishi,1 Yuki Matsuda,1 Kiyoshi Fujita,2,3 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan; 3The Neuroscience Research Center, Toyoake, Aichi, Japan Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia. Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic naïve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.Results: Thirty-seven patients were recruited (56.8% of them had first-episode schizophrenia), and 28 (75.7%) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9% of patients showed a ≥20% reduction in the PANSS total score and 48.6% showed a ≥30% reduction. However, 8.1% of patients experienced at least one adverse event. Using the 20% reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9% and 94.1%, respectively. The specificities were 80.0% and 51.6%, respectively.Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8. Keywords: efficacy, safety, antipsychotic Kishi TMatsuda YFujita KIwata NDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1861-1866 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kishi T Matsuda Y Fujita K Iwata N Early prediction of blonanserin response in Japanese patients with schizophrenia
description	Taro Kishi,1 Yuki Matsuda,1 Kiyoshi Fujita,2,3 Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan; 3The Neuroscience Research Center, Toyoake, Aichi, Japan Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia in Japan and Korea. The present study aimed to examine early prediction of blonanserin in patients with schizophrenia. Methods: An 8-week, prospective, single-arm, flexible-dose clinical trial of blonanserin in patients with schizophrenia was conducted under real-world conditions. The inclusion criteria were antipsychotic naïve, and first-episode schizophrenia patients or schizophrenia patients with no consumption of any antipsychotic medication for more than 4 weeks before enrollment in this study. The positive predictive value, negative predictive value, sensitivity, specificity, and predictive power were calculated for the response status at week 4 to predict the subsequent response at week 8.Results: Thirty-seven patients were recruited (56.8% of them had first-episode schizophrenia), and 28 (75.7%) completed the trial. At week 8, blonanserin was associated with a significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score (P<0.0001) and in positive (P<0.0001), negative (P<0.0001), and general subscale scores (P<0.0001). In terms of percentage improvement of PANSS total scores from baseline to week 8, 64.9% of patients showed a ≥20% reduction in the PANSS total score and 48.6% showed a ≥30% reduction. However, 8.1% of patients experienced at least one adverse event. Using the 20% reduction in the PANSS total score at week 4 as a definition of an early response, the negative predictive values for later responses (ie, reductions of ≥30 and ≥40 in the PANSS total scores) were 88.9% and 94.1%, respectively. The specificities were 80.0% and 51.6%, respectively.Conclusion: Our results suggest that the blonanserin response at week 4 could predict the later response at week 8. Keywords: efficacy, safety, antipsychotic
format	article
author	Kishi T Matsuda Y Fujita K Iwata N
author_facet	Kishi T Matsuda Y Fujita K Iwata N
author_sort	Kishi T
title	Early prediction of blonanserin response in Japanese patients with schizophrenia
title_short	Early prediction of blonanserin response in Japanese patients with schizophrenia
title_full	Early prediction of blonanserin response in Japanese patients with schizophrenia
title_fullStr	Early prediction of blonanserin response in Japanese patients with schizophrenia
title_full_unstemmed	Early prediction of blonanserin response in Japanese patients with schizophrenia
title_sort	early prediction of blonanserin response in japanese patients with schizophrenia
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/58f3f0ce357944898f5ac8cb40e305f7
work_keys_str_mv	AT kishit earlypredictionofblonanserinresponseinjapanesepatientswithschizophrenia AT matsuday earlypredictionofblonanserinresponseinjapanesepatientswithschizophrenia AT fujitak earlypredictionofblonanserinresponseinjapanesepatientswithschizophrenia AT iwatan earlypredictionofblonanserinresponseinjapanesepatientswithschizophrenia
_version_	1718395227473969152

Early prediction of blonanserin response in Japanese patients with schizophrenia

Ejemplares similares